Therapeutic choice of axillary treatment after neoadjuvant chemotherapy in patients with node-positive breast cancer
10.3969/j.issn.1000-8179.2019.05.050
- VernacularTitle:腋窝淋巴结阳性乳腺癌新辅助化疗后腋窝治疗选择的研究
- Author:
Hao ZHOU
1
;
Zujin CHEN
;
Yun LI
;
Yuting WANG
;
Di ZHANG
;
Xuchen CAO
;
Xin WANG
Author Information
1. 天津医科大学肿瘤医院乳腺一科
- Keywords:
breast cancer;
neoadjuvant chemotherapy;
lymphatic metastasis;
sentinel lymph node biopsy (SLNB)
- From:
Chinese Journal of Clinical Oncology
2019;46(5):247-251
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the feasibility of axillary lymph node staging through sentinel lymph node biopsy (SLNB) after neoad-juvant chemotherapy (NAC) in patients with node-positive breast cancer and to explore the follow-up treatment of these patients. Methods: Clinical data of 82 patients with node-positive breast cancer before NAC in Tianjin Medical University Cancer Institute and Hospital from January 2016 to January 2018 were analyzed retrospectively. All these patients accepted SLNB after NAC. The detection rate, accuracy, false negative rate (FNR), and influencing factors were analyzed. Results: A nodal pathological complete response (PCR) was achieved in 43 of 82 patients. The PCR rate was 52.4%. The detection rate, accuracy, and FNR were 97.56% (80/82), 88.75% (71/80), and 23.08% (9/39), respectively. The accuracy of 1, 2, and≥3 SLNs detected were 90.9% (20/22), 66.7% (10/15), and 95.3% (41/43), respectively. The FNRs were 20.0% (2/10), 71.4% (5/7), and 9.1% (2/22), respectively (both P<0.05). Conclusions: Due to its overall high FNR, without clinically acceptable limits, post-NAC SLNB cannot completely replace axillary lymph node dissection (ALND) in node-positive patients. However, with no less than 3 SLNs detected, SLNB can accurately evaluate the status of axillary lymph nodes.
